Navidea Biopharmaceuticals, Inc. (NAVB) Financial Analysis and Rating

Comparison Analysis Based on SEC Data

Company Name Navidea Biopharmaceuticals, Inc.
Industry (SIC) 2835 - In Vitro and In Vivo Diagnostic Substances
Revenue in 2022 $66 thousand (ranked #616 out of 644 companies in the industry)
Assets as of 12/31/2022 $4,372 thousand (ranked #598)
Analyzed report 12/31/2021 (filed 3/28/2022)

Year:
20212022

Financial Position and Performance
Annual | Quarterly

Compared with 2021 industry ratios Change during the year

much worse
unchanged
Compared with all listed companies

much worse

Compare with a competitor

Financial Ratios Benchmarking

Financial Ratio Comparison of company ratios for 2021
with industry ratios
(28 - Chemicals And Allied Products) 		with all listed companies
Solvency Ratios
Debt ratio 
0.91
0.35
0.91
0.57
Debt-to-equity ratio 
9.64
0.35
9.64
0.93
Interest coverage ratio 
-31.01
-9.63
-31.01
3.04
Liquidity Ratios
Current Ratio 
1.02
4.55
1.02
2.03
Cash Ratio 
0.80
3.76
0.80
0.82
Profitability Ratios
Profit margin 
-2207.1%
-138.2%
-2207.1%
5.2%
ROE (Return on equity), after tax 
-878.2%
-54.3%
-878.2%
2.6%
ROA (Return on assets) 
-162.9%
-33.2%
-162.9%
1.1%
Activity Ratios
Asset turnover (days) 
4945
1676
4945
815
Resulting score -1,8 -1,8

Year:
20212022

Additional Ratios (not used in score calculation)

Financial Ratio Comparison of company ratios for 2021
with industry ratios
(28 - Chemicals And Allied Products) 		with all listed companies
Profitability Ratios
Operating margin (Return on sales) 
-2135.2%
-29.6%
-2135.2%
9.7%
Activity Ratios
EBIT  $(11)M
EBITDA  $(11)M

Auditor's Conclusion

We have performed a comparative analysis of the balance sheet and income statement of Navidea Biopharmaceuticals, Inc. (hereafter – the "Company") for the year 2021 as filed with the U.S. Securities and Exchange Commission (SEC). The primary business activity of the Company is "In Vitro and In Vivo Diagnostic Substances" (SIC code 2835). In our analysis, we compared the key financial ratios of the Company with the average (median) values of those ratios calculated for the Company's specific industry sector and for all companies. The averages were calculated using data from 2021 financial statements filed with the SEC through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). By comparing each of the eleven key metrics to the median, we have reached an overall conclusion about the quality of the Company's financial condition. All calculations and conclusions were performed using software and methodologies developed by ReadyRatios.

Based on our analysis of the Company's key financial ratios, we have determined the following. The financial condition of Navidea Biopharmaceuticals, Inc. in 2021 is much worse than the typical financial condition of companies in the "In Vitro and In Vivo Diagnostic Substances" industry.

The same conclusion can be reached when comparing the Company's ratios to the averages for all U.S. industries. The financial position of Navidea Biopharmaceuticals, Inc. is much worse than that of most listed companies that file financial statements with the U.S. Securities and Exchange Commission.

Financial Position and Performance History


More on Navidea Biopharmaceuticals, Inc.

Closest Competitors

Company USD ($), in Millions